Every Form 4 that PHARM-BIO SERV INC (PBSV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PBSV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBSV filings page.
SPINDEL HOWARD reported disposition transactions in this Form 4 filing.
Pharma-Bio Serv, Inc. director Howard Spindel reported an estate-related restructuring of holdings in the company’s common stock. On 2026-06-09, 42,504 shares previously reported as indirectly owned through his spouse were transferred to the couple’s adult children at $0.00 per share. Following this transfer, Spindel reports 0 shares of common stock owned. He expressly disclaims beneficial ownership of the transferred shares, stating this report should not be deemed an admission that he is their beneficial owner for Section 16 or any other purpose.
Pharma-Bio Serv, Inc. reported an insider equity award for Chairman and director Kirk Michel. On January 10, 2026, he received a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share, expiring on January 10, 2031. The option vests in two equal installments on July 10, 2026 and July 10, 2027, meaning half of the option becomes exercisable on each of those dates.
Pharma-Bio Serv, Inc. reported a routine insider equity award for director Dov Perlysky. On January 10, 2026, he was granted a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share. The option vests in two equal installments on July 10, 2026 and July 10, 2027, and expires on January 10, 2031. Following this grant, Perlysky beneficially owns 20,000 derivative securities directly in the form of this option.
Pharma-Bio Serv, Inc. director Howard Spindel reported a new stock option grant. On January 10, 2026, he was awarded 20,000 stock options with an exercise price of $0.54 per share, each option corresponding to one share of common stock.
The options vest in two equal installments on July 10, 2026 and July 10, 2027, meaning half become exercisable on each of those dates. Following this grant, Spindel beneficially owns 20,000 derivative securities, held directly, according to the report.
Pharma-Bio Serv, Inc. director Irving L. Wiesen reported a new stock option grant on a Form 4. On January 10, 2026, he received a stock option for 20,000 shares of Pharma-Bio Serv common stock. The option has an exercise price of $0.54 per share and an expiration date of January 10, 2031.
According to the filing, the option vests in two equal installments on July 10, 2026 and July 10, 2027. After this grant, Wiesen beneficially owns 20,000 derivative securities related to these options, held in direct ownership.